Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure

• Status: Unknown status
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the therapeutic efficacy of allogenic bone marrow stem cells (BMSCs) transplantation in patients with liver failure caused by hepatitis B infection. The evaluation of the efficacy includes the level of serum alanine aminotransferase (ALT), aspartate aminotransferase(AST), total bilirubin (TB),prothrombin time (PT), albumin (ALB), prealbumin(PA), liver histological improvement before and 1 week to 1 year after transplantation. Child-Pugh scores, MELD scores and clinical symptoms were also observed simultaneously.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University

Criteria

Inclusion Criteria:

• Aged 16~65 years.

• Serum HBsAg positive for over six months.

• Meet the diagnostic criteria of liver failure:

Exclusion Criteria:

• History of moderate to severe hepatic encephalopathy or variceal bleeding during the last two months before enrolment.

• Prothrombin time is over 30s.

• Cirrhosis caused by other reasons except HBV infection.

• Severe problems in other vital organs(e.g.the heart,renal or lungs).

• Liver tumor on ultrasonography, CT or MRI examination.

• Pregnant or lactating women.

• Imaging evidences of vascular thromboses.